论文部分内容阅读
本刊讯近期,食品药品监督管理部门监测到承德御室金丹药业有限公司生产的药品“气血双补丸”、天津同仁堂集团股份有限公司生产的药品“冠脉通片”、红桃开药业股份有限公司生产的药品“两仪膏”、通化久铭药业有限公司生产的药品“舒心宁片(广告中标示名称:祺新丹)”、通化颐生药业股份有限公司生产的药品“理气舒心片”、广西中医药大学制药厂生产的药品“复方扶芳藤合剂”等6起药品广告宣传内容均含有不科学的功效断言,扩大宣传治愈率或有效率,利用患者名义或形象做功效证明等问题,欺骗和误导消费者,
Recently, the food and drug supervision and management departments to monitor drugs produced by Chengde Royal Jade Dan Pharmaceutical Co., Ltd., “blood and blood Shuangfu Wan”, Tianjin Tong Ren Tang Group Co., Ltd. production of drugs “coronary pulse” Pharmaceutical Co., Ltd. of Hongtaowu Pharmaceutical Co., Ltd. “,” two instruments cream “, Tonghua Jiu Ming Pharmaceutical Co., Ltd. production of drugs” Shuxin Ning tablets (advertising name: Qi Xin Dan) Health Pharmaceutical Co., Ltd. produced the drug “Qi gastronomy tablets ”, Guangxi University of Traditional Chinese Medicine pharmaceutical production “compound Fu Fang vine mixture ” and other 6 drugs advertising content contains unscientific assertion of efficacy, Expand publicity cure rate or efficiency, use the name or image of the patient to prove efficacy and other issues, to deceive and mislead consumers,